EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer.

Adequate test sensitivity may be achieved with lower NGS coverage depth in the case of deceased index patient testing on non-neoplastic tissue; however, failure rates due to technical challenges associated with FFPE tissue analysis may be significant [ 46 ]. 4.2 Specific Variant Testing (predictive testing) Where a causative PV has been identified in an index case, predictive testing for at-risk family members can be offered.

also in 13,097 other papers